Entero Therapeutics, Inc.
ENTO
$0.3541
-$0.0241-6.37%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -12.24M | -2.58M | -8.81M | 5.57M | -4.10M |
| Total Depreciation and Amortization | -34.30K | 1.30K | 35.30K | 12.30K | 7.30K |
| Total Amortization of Deferred Charges | 0.00 | 0.00 | 5.80K | -- | -- |
| Total Other Non-Cash Items | 10.70M | 201.00K | 5.17M | -9.78M | 159.70K |
| Change in Net Operating Assets | 1.40M | 530.20K | 147.90K | 451.10K | 494.50K |
| Cash from Operations | -171.50K | -1.85M | -3.45M | -3.75M | -3.44M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | 0.00 | 88.20K | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -500.00K |
| Cash from Investing | 0.00 | 0.00 | 0.00 | 88.20K | -500.00K |
| Total Debt Issued | -- | 0.00 | 31.80K | -- | -- |
| Total Debt Repaid | 0.00 | -177.60K | -241.00K | -226.00K | 0.00 |
| Issuance of Common Stock | 0.00 | 1.73M | 890.60K | 3.60M | 4.36M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -31.80K | 1.55M | 681.40K | 3.38M | 4.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -203.30K | -295.70K | -2.77M | -279.90K | 419.40K |